Metabolic Syndrome in Patients with Polycystic Ovary Syndrome in Iran
Authors
Abstract:
Background The prevalence of metabolic syndrome (MetS) in polycystic ovary syndrome (PCOS) has been studied in different populations, but their results were so controversial regarding Iranian women. These controversial data indicated the need for more investigation of MetS characteristics in PCOS patients in our population. So this study aimed to evaluate the clinical and laboratory characteristics and metabolic features of patients with PCOS in Rasht. MaterialsAndMethods This prospective cross sectional study was conducted on 215 PCOS women who lived in Rasht, north of Iran, from March 2010 to July 2012. The participants were then divided into two groups of women with MetS (n=62) and women without MetS (n=153). The diagnosis of PCOS and MetS were based on the Rotterdam 2003 criteria and the Adult Treatment Panel III (ATP III) criteria, respectively. Demographic characteristics, fertility characteristics, family history and laboratory findings were assessed. Results The prevalence of MetS in women with PCOS was 28.8%. In PCOS women of both groups, the waist circumference (WC) exceeded 88cm in 72.6%, hypertension [systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) ≥130/85mm Hg] was prevalent in 9.3%, fasting blood sugar (FBS) level was ≥110 mg/dl in 6%, triglycerides (Tg) level were ≥150 mg/dl in 47%, and high-density lipoprotein (HDL) level was
similar resources
Metabolic Syndrome in Patients with Polycystic Ovary Syndrome in Iran.
BACKGROUND The prevalence of metabolic syndrome (MetS) in polycystic ovary syndrome (PCOS) has been studied in different populations, but their results were so controversial regarding Iranian women. These controversial data indicated the need for more investigation of MetS characteristics in PCOS patients in our population. So this study aimed to evaluate the clinical and laboratory characteris...
full textmetabolic syndrome in patients with polycystic ovary syndrome in iran
background: the prevalence of metabolic syndrome (mets) in polycystic ovary syndrome (pcos) has been studied in different populations, but their results were so controversial regarding iranian women. these controversial data indicated the need for more investigation of mets characteristics in pcos patients in our population. so this study aimed to evaluate the clinical and laboratory characteri...
full textP-54: Metabolic Abnormalities in Adolescents with Polycystic Ovary Syndrome in Zanjan-Iran
Background: Adults with polycystic ovary syndrome (PCOS) can have multiple metabolic abnormalities. However, studies in the adolescent population are still limited and these results seem to vary widely. This study was to investigate the metabolic abnormalities in adolescents with PCOS in Zanjan-Iran and potential risk factors contributed to these health risks. Materials and Methods: Anthropomet...
full textI-30: Prevalence of Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Background: Metabolic syndrome is a disorder which is composed of several metabolic abnormalities: glucose intolerance, dyslipidemia, obesity and hypertension. PCOS which is characterized by menstrual irregularities and hyperandrogenism, is a common endocrinological disorder in female reproductive age. The prevalence of the syndrome is 5-10%. Insulin resistance is a common feature of the PCOS (...
full textThe comparison of dietary intake of macronutrients in polycystic ovary syndrome with and without metabolic syndrome
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive age women. The prevalence of PCOS among Iranian women is 14.6% based on the Rotterdam definition. PCOS can increase the risk of chronic metabolic complications. Metabolic syndrome (MetS) is one of the most important of them. Insulin resistance is fundamental in PCOS and MetS pathophysiology. MetS ...
full textMy Resources
Journal title
volume 9 issue 4
pages 490- 496
publication date 2016-12-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023